Pharmaceutical company Eli Lilly’s study of its tablet, orforglipron, has raised hopes of an effective and easy-to-use treatment reaching a market dominated by injections.

The company’s shares jumped 13.3% as the results of the trial, the first of several under way on the pill, orforglipron, raised hopes of an easy-to-use treatment reaching a market dominated by injecti

Eli Lilly said its experimental drug, orforglipron, helped people with Type 2 diabetes lower their blood sugar and lose weight. The company is hoping to bring the first GLP-1 weight-loss pill to market,